<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31818462</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>522</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Cephalotaxine inhibits Zika infection by impeding viral replication and stability.</ArticleTitle><Pagination><StartPage>1052</StartPage><EndPage>1058</EndPage><MedlinePgn>1052-1058</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2019.12.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(19)32332-0</ELocationID><Abstract><AbstractText>The Zika virus (ZIKV) is a mosquito-borne flavivirus that has reemerged as a serious public health problem around the world. Syndromes of infected people range from asymptomatic infections to severe neurological disorders, such as Guillain-Barr&#xe9; syndrome and microcephaly. Screening anti-ZIKV drugs derived from Chinese medicinal herbs is one method of identifying antiviral agents. In this paper, we report that (1) Cephalotaxine (CET), an alkaloid isolated from Cephalotaxus drupacea, was effective in inhibiting ZIKV activity in&#xa0;vitro (i.e., in Vero and A549&#xa0;cell lines) and (2) the mechanisms which underlie these effects involve virucidal activity and a decrease in viral replication. Specifically, CET was found to decrease ZIKV RNA and viral protein expression, inhibit ZIKV replication, and inhibit ZIKV mRNA/protein production. We also determined that CET is effective in inhibiting dengue virus 1-4 (DENV1-4). Taken together, our findings indicate that CET could be an effective lead compound in the treatment of ZIKV and also suggest that further investigation and development of CET-derived drugs may lead to a new class of anti-Flavivirus medications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Zheng-Zong</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>Department and Graduate Institute of Pharmacology, National Defense Medical Center, Taipei, Taiwan, ROC; Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Yi-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, ROC; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jeng-Wei</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Singapore. Electronic address: jengweilu@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>6FG8041S5B</RegistryNumber><NameOfSubstance UI="D000077863">Homoharringtonine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077863" MajorTopicYN="N">Homoharringtonine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012703" MajorTopicYN="N">Serotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Cephalotaxine</Keyword><Keyword MajorTopicYN="N">Dengue virus</Keyword><Keyword MajorTopicYN="N">Replication</Keyword><Keyword MajorTopicYN="N">Viral production</Keyword><Keyword MajorTopicYN="N">Zika virus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31818462</ArticleId><ArticleId IdType="pmc">PMC7092853</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2019.12.012</ArticleId><ArticleId IdType="pii">S0006-291X(19)32332-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dick G.W., Kitchen S.F., Haddow A.J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 1952;46:509&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12995440</ArticleId></ArticleIdList></Reference><Reference><Citation>Espano E., Nam J.H., Song E.J., Song D., Lee C.K., Kim J.K. Lipophilic statins inhibit Zika virus production in Vero cells. Sci. Rep. 2019;9:11461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685969</ArticleId><ArticleId IdType="pubmed">31391514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno G., Chang G.J. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch. Virol. 2007;152:687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">17195954</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen L.R., Jamieson D.J., Powers A.M., Honein M.A. Zika virus. N.&#xa0;Engl. J. Med. 2016;374:1552&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pubmed">27028561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessey M., Fischer M., Staples J.E. Zika virus spreads to new areas - region of the americas, may 2015-january 2016. MMWR Morb. Mortal. Wkly. Rep. 2016;65:55&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">26820163</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira M.G., Costa Mda C., de Oliveira W.K., Nunes M.L., Rodrigues L.C. The epidemic of Zika virus-related microcephaly in Brazil: detection, control, etiology, and future scenarios. Am. J. Public Health. 2016;106:601&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4816003</ArticleId><ArticleId IdType="pubmed">26959259</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria N.R., Azevedo R., Kraemer M.U.G., Souza R., Cunha M.S., Hill S.C., Theze J., Bonsall M.B., Bowden T.A., Rissanen I., Rocco I.M., Nogueira J.S., Maeda A.Y., Vasami F., Macedo F.L.L., Suzuki A., Rodrigues S.G., Cruz A.C.R., Nunes B.T., Medeiros D.B.A., Rodrigues D.S.G., Queiroz A.L.N., da Silva E.V.P., Henriques D.F., da Rosa E.S.T., de Oliveira C.S., Martins L.C., Vasconcelos H.B., Casseb L.M.N., Simith D.B., Messina J.P., Abade L., Lourenco J., Alcantara L.C.J., de Lima M.M., Giovanetti M., Hay S.I., de Oliveira R.S., Lemos P.D.S., de Oliveira L.F., de Lima C.P.S., da Silva S.P., de Vasconcelos J.M., Franco L., Cardoso J.F., Vianez-Junior J., Mir D., Bello G., Delatorre E., Khan K., Creatore M., Coelho G.E., de Oliveira W.K., Tesh R., Pybus O.G., Nunes M.R.T., Vasconcelos P.F.C. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352:345&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918795</ArticleId><ArticleId IdType="pubmed">27013429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.L., Loe M.W.C., Lee R.C.H., Chu J.J.H. Antiviral activity of pinocembrin against Zika virus replication. Antivir. Res. 2019;167:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30959074</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Liang Y., Yi P., Xu L., Hawkins H.K., Rossi S.L., Soong L., Cai J., Menon R., Sun J. Outcomes of congenital Zika disease depend on timing of infection and maternal-fetal interferon action. Cell Rep. 2017;21:1588&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726784</ArticleId><ArticleId IdType="pubmed">29117563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibueze E.C., Tirado V., Lopes K.D., Balogun O.O., Takemoto Y., Swa T., Dagvadorj A., Nagata C., Morisaki N., Menendez C., Ota E., Mori R., Oladapo O.T. Zika virus infection in pregnancy: a systematic review of disease course and complications. Reprod. Health. 2017;14:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330035</ArticleId><ArticleId IdType="pubmed">28241773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammarchi L., Stella G., Mantella A., Bartolozzi D., Tappe D., Gunther S., Oestereich L., Cadar D., Munoz-Fontela C., Bartoloni A., Schmidt-Chanasit J. Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. J.&#xa0;Clin. Virol. 2015;63:32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25600600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura C.V., Maia M., Bravo-Filho V., Gois A.L., Belfort R., Jr. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet. 2016;387:228.</Citation><ArticleIdList><ArticleId IdType="pubmed">26775125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zika virus infection: global update on epidemiology and potentially associated clinical manifestations. Wkly. Epidemiol. Rec. 2016;91:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26897760</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista M.N., Braga A.C.S., Campos G.R.F., Souza M.M., Matos R.P.A., Lopes T.Z., Candido N.M., Lima M.L.D., Machado F.C., Andrade S.T.Q., Bittar C., Nogueira M.L., Carneiro B.M., Mariutti R.B., Arni R.K., Calmon M.F., Rahal P. Natural products isolated from oriental medicinal herbs inactivate Zika virus. Viruses. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6356660</ArticleId><ArticleId IdType="pubmed">30641880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J.&#xa0;Hematol. Oncol. 2014;7:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884015</ArticleId><ArticleId IdType="pubmed">24387717</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero M.R., Serrano M.A., Efferth T., Alvarez M., Marin J.J. Effect of cantharidin, cephalotaxine and homoharringtonine on "in&#xa0;vitro" models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. Planta Med. 2007;73:552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">17458779</ArticleId></ArticleIdList></Reference><Reference><Citation>Perard-Viret J., Quteishat L., Alsalim R., Royer J., Dumas F. Cephalotaxus alkaloids. Alkaloids Chem. Biol. 2017;78:205&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110560</ArticleId><ArticleId IdType="pubmed">28838429</ArticleId></ArticleIdList></Reference><Reference><Citation>Efferth T., Sauerbrey A., Halatsch M.E., Ross D.D., Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol. 2003;367:56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12616342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur P., Thiruchelvan M., Lee R.C., Chen H., Chen K.C., Ng M.L., Chu J.J. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob. Agents Chemother. 2013;57:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535938</ArticleId><ArticleId IdType="pubmed">23275491</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Forrest J.C., Zhang X. A&#xa0;screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antivir. Res. 2015;114:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113785</ArticleId><ArticleId IdType="pubmed">25451075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.E., Song Y.J. Anti-varicella-zoster virus activity of cephalotaxine esters in&#xa0;vitro. J.&#xa0;Microbiol. 2019;57:74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090801</ArticleId><ArticleId IdType="pubmed">30456755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y.J., Liu F.C., Yeh C.T., Yang C.M., Lin C.C., Lin T.Y., Hsieh P.S., Hu M.K., Gong Z., Lu J.W. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antivir. Res. 2018;159:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">30300716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y.J., Lu J.W., Huang Y.L., Lai Z.Z. Palmatine inhibits Zika virus infection by disrupting virus binding, entry, and stability. Biochem. Biophys. Res. Commun. 2019;518:732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">31472967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J.W., Hsieh P.S., Lin C.C., Hu M.K., Huang S.M., Wang Y.M., Liang C.Y., Gong Z., Ho Y.J. Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem. Biophys. Res. Commun. 2017;491:595&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">28760340</ArticleId></ArticleIdList></Reference><Reference><Citation>Adcock R.S., Chu Y.K., Golden J.E., Chung D.H. Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay. Antivir. Res. 2017;138:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27919709</ArticleId></ArticleIdList></Reference><Reference><Citation>Agbulos D.S., Barelli L., Giordano B.V., HunCurr F.F. Zika virus: quantification, propagation, detection, and storage. Curr. Protoc. Microbiol. 2016;43 15D 14 11-15D.</Citation><ArticleIdList><ArticleId IdType="pubmed">27858969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fresno M., Jimenez A., Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 1977;72:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">319998</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia K., Yuan Y., Liu W., Liu L., Qin Q., Yi M. Identification of inhibitory compounds against Singapore grouper iridovirus infection by cell viability-based screening assay and droplet digital PCR. Mar. Biotechnol. 2018;20:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">29209860</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M.T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 1975;11:511&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">1237080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D.C., Zittoun R., Marie J.P. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull. Cancer. 1995;82:987&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pubmed">8745664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>